Better outcomes and fewer failures drive innovation in rheumatoid arthritis
This article was originally published in Scrip
While market-leading anti-tumor necrosis factor (TNF) agents such as Humira (adalimumab; AbbVie/Eisai) and Enbrel (etanercept; Amgen/Pfizer/Takeda) have revolutionized the treatment of rheumatoid arthritis, there continues to be a significant unmet need for novel therapies that are associated with fewer treatment failures and inadequate responders. Recent Datamonitor Healthcare analysis of the early phase rheumatoid arthritis pipeline has identified the most commercially attractive opportunities in this therapy area, all still at a relatively early stage of investigation. "Recent innovation in the rheumatoid arthritis market is focused on demonstrating a superior clinical profile to the well-established anti-TNFs through biologics with novel mechanisms of action or novel oral small molecules," Datamonitor Healthcare analyst Christina Vasiliou told Scrip.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.